Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbonyl reductase family member 4 (CBR4)
- Target
- CBR4
- Molecular classification
- Enzyme, Short-chain dehydrogenase/reductase superfamily, Mitochondrial protein
01
Overview
Carbonyl reductase family member 4 (CBR4) is a mitochondrial enzyme of the short-chain dehydrogenase/reductase superfamily. CBR4 forms a tetrameric structure, where it acts as a NADPH-dependent quinone reductase, preferring ortho- and para-quinones as substrates rather than other aldehydes or ketones. This reduction can generate reactive oxygen species through redox cycling, contributing to apoptosis under cytotoxic stress. Functionally, CBR4 also serves as the beta subunit in the mitochondrial 3-ketoacyl-[acyl-carrier-protein] reductase complex, where, alongside the alpha subunit HSD17B8, it is essential for mitochondrial fatty acid synthesis. CBR4 plays key roles in redox homeostasis, cellular defense against toxicants, and metabolic processes, with potential implications in cancer biology and other disease contexts.
- Other names
- 3-oxoacyl-[acyl-carrier-protein] reductase3-ketoacyl-[acyl-carrier-protein] reductase beta subunitSDR45C1KAR beta subunitFLJ14431Quinone reductase CBR4Short chain dehydrogenase/reductase family 45C member 1
02
Mechanism of action
NADPH-dependent reduction of ortho- and para-quinones Contribution to superoxide generation via redox cycling Reductive conversion of 3-oxoacyl-ACP intermediates in mitochondrial fatty acid synthesis
03
Biological functions
Fatty acid biosynthesis (mitochondrial)Detoxification of quinonesRedox homeostasisProtein tetramerizationCellular defense against toxicantsMetabolism of endogenous and xenobiotic carbonyl compounds
04
Disease associations
Cancer (e.g., glioblastoma prognosis indicator in regorafenib treatment)Apoptosis (response to cytotoxic quinones)Other metabolic disorders (potential roles inferred from general SDR functions)
05
Safety considerations
Superoxide formation during quinone reduction can lead to apoptosis and oxidative stress, posing challenges for therapeutic modulationPotential impact on mitochondrial and fatty acid metabolism if inhibited
06
Interacting drugs
Regorafenib
2 more in the full profile.
07
Biomarkers
Expression of CBR4 is a candidate biomarker for response and prognosis in glioblastoma patients treated with regorafenib
Beyond the preview
Go deeper on Carbonyl reductase family member 4 (CBR4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carbonyl reductase family member 4 (CBR4).